SSY Group says China regulator approves Baloxavir Marboxil bulk drug registration

• SSY Group secured China NMPA registration approval for Baloxavir Marboxil as a bulk drug for marketed formulations.
• The API is used to treat influenza A and influenza B; it is the group’s third such approval for PRC entities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12242103), on July 13, 2026, and is solely responsible for the information contained therein.